Atlas Trials

Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

Clinical trial NCT06829641 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06829641
Sponsor
West China Hospital
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
NSCLC Stage IIIB, NSCLC Stage IIIC
Start date
2025-08-09
Primary completion
2025-12-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.